<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Article Put a cork in it: Plugging the M2" exact="viral" post="ion channel to sink influenza JalilyPouria H.aDuncanMaggie C.bFedidaDavidaWangJuncTietjenIanitietjen@wistar.orgbd∗[a], [b],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="A is a proton-gated proton channel that is required for" exact="viral" post="replication. •Current influenza strains are resistant to licensed M2"/>
 <result pre="2017–2018 seasonal outbreak which is estimated by the Centers for" exact="Disease" post="Control and Prevention to have caused approximately 710,000 hospitalizations"/>
 <result pre="less common but historically regular pandemic outbreaks in populations with" exact="limited" post="or no immunity that can result in hundreds of"/>
 <result pre="significantly affecting M2 ion channel activity or the fitness of" exact="viral" post="replication (Balannik et al., 2010; Grambas et al., 1992;"/>
 <result pre="understood, they are generally involved in conducting ions to facilitate" exact="viral" post="entry, assembly, and/or release from host cells. Table 1"/>
 <result pre="Coronaviridae SARS-CoV E, 3a, 8a Castaño-Rodriguez et al. (2018) Flaviviridae" exact="Hepatitis" post="C virus p7 Madan et al. (2015) Orthomyxoviridae IAV"/>
 <result pre="(2011) Picornaviridae Poliovirus 2 B Aldabe et al. (1996) Pneumoviridae" exact="Respiratory" post="syncytial virus Small hydrophobic (SH) protein Gan et al."/>
 <result pre="al. (2012) Polyomaviridae JC polyomavirus Agnoprotein Suzuki et al. (2010)" exact="Reoviridae" post="Avian reovirus p10 Bodelón et al. (2002) Retroviridae HIV-1"/>
 <result pre="(2012) Polyomaviridae JC polyomavirus Agnoprotein Suzuki et al. (2010) Reoviridae" exact="Avian" post="reovirus p10 Bodelón et al. (2002) Retroviridae HIV-1 Vpu"/>
 <result pre="Bodelón et al. (2002) Retroviridae HIV-1 Vpu Strebel (2014) Rhabdoviridae" exact="Bovine" post="ephemeral fever virus α1 Joubert et al. (2014) 2.1"/>
 <result pre="best understood viroporin. It consists of a 97 amino acid," exact="type I" post="transmembrane domain-containing protein which forms a tetrameric ion channel"/>
 <result pre="one or more distinct function(s) (Wang et al., 2011c). Following" exact="viral" post="entry, M2 expressed on the virion membrane transports protons"/>
 <result pre="2 ). This low pH environment facilitates conformational changes in" exact="viral" post="hemagglutinin (HA) and dissociation of viral ribonucleoprotein complex from"/>
 <result pre="facilitates conformational changes in viral hemagglutinin (HA) and dissociation of" exact="viral" post="ribonucleoprotein complex from M1 proteins to promote virion membrane"/>
 <result pre="M1 proteins to promote virion membrane fusion and release of" exact="viral" post="RNA into the host cell. M2 proton gating function"/>
 <result pre="1996; Gutman et al., 1993; Martin and Heleniust, 1991). During" exact="viral" post="egress, M2 also equilibrates the pH of trans-Golgi lumina"/>
 <result pre="where increased proton conductance by M2 correlates with more acid" exact="labile" post="HA sequences (Grambas et al., 1992; Scholtissek et al.,"/>
 <result pre="membrane curvature leading to membrane scission and release of new" exact="viral" post="progeny (Chen et al., 2008; Rossman and Lamb, 2011;"/>
 <result pre="by K+ to allow for the subsequent release of the" exact="viral" post="ribonucleoprotein bundle (Stauffer et al., 2014). Fig. 2 Overview"/>
 <result pre="of wild-type (WT) and drug-resistant A/M2 proteins available in the" exact="Protein" post="Data Bank (PDB). Most of these were solved by"/>
 <result pre="channel to the &quot;activated state&quot;, resulting in the formation of" exact="stable" post="cation-p interactions between His37 and Trp41. The Trp41 tetrad"/>
 <result pre="2014). During virus entry, amantadine's inhibition of M2 results in" exact="incomplete" post="dissociation of M1 from ribonucleoprotein complexes, which in turn"/>
 <result pre="network and the cytoplasm, amantadine-based M2 inhibition may also disrupt" exact="viral" post="egress (Lamb, R.A. and Krug, 2001; Takeda et al.,"/>
 <result pre="35 μM A/Udorn/72 NR Wang et al. (2013b) PRA WT:" exact="complete" post="inhibition at 1 μMS31N: 3.2 μM A/WSN/33 8 BC035"/>
 <result pre="FDA approval in 1966 under the brand name &quot;Symmetrel&quot; for" exact="systemic" post="use in humans for prophylaxis of Asian influenza (H2N2)"/>
 <result pre="confers adamantane resistance by decreasing the pore size and occluding" exact="stable" post="access of amantadine to the pore (Stouffer et al.,"/>
 <result pre="an alternative but initially controversial binding mechanism for adamantanes, located" exact="external" post="to the M2 pore, was also proposed (Pielak et"/>
 <result pre="was the preferred binding site (PDB: 2KQT), where amantadine preferentially" exact="localized" post="to a hydrophobic cage formed by Ala30, Ser31, and"/>
 <result pre="high amantadine concentrations and were thus less probable as the" exact="primary" post="mode of M2 inhibition. In further support of the"/>
 <result pre="barrier for binding was minimal, and drug binding was less" exact="stable" post="and more readily dissociated. Moreover, the initial NMR structure"/>
 <result pre="an intraluminal binding site but rather binding at the allosteric" exact="peripheral" post="site in the lipid interface. However, this can also"/>
 <result pre="In contrast to the Val27Ala single mutation that results in" exact="complete" post="resistance to amantadine, M2 sequences containing Ser31Asn can still"/>
 <result pre="and DeGrado, 2016; Thomaston et al., 2018, 2019), in the" exact="absence of" post="a drug molecule in the pore and in the"/>
 <result pre="μM against the A/WSN/33 M2 Ser31Asn strain of IAV and" exact="complete" post="inhibition of WT (Ser31 M2-containing) virus at 1 μM."/>
 <result pre="an occasional Asn31Ser mutation which reverted back to Asn31 upon" exact="drug withdrawal." post="In contrast, passaging with the dual inhibitor compound 8"/>
 <result pre="resulted in Asn31Asp and Ile32Thr mutations which also reverted after" exact="drug withdrawal" post="(Ma et al., 2016). Both sets of mutations were"/>
 <result pre="+ Val27Ile or Leu26Ile exhibited similar proton conductance properties and" exact="viral" post="replication fitness relative to the single Ser31Asn mutant, the"/>
 <result pre="and Leu26Ile resulted in substantially reduced M2 proton conductance and" exact="viral" post="replication. These observations may suggest that the viable evolutionary"/>
 <result pre="synergized with oseltamivir, raising the possibility of combination therapies where" exact="lower" post="doses of drugs can be used to minimize the"/>
 <result pre="to 100 mg/kg/day, compound 9 also rescued mice from lethal" exact="infection" post="of viruses containing either WT M2 or M2 Val27Ala,"/>
 <result pre="are encouraging, in vivo results for most adamantane derivatives remain" exact="limited" post="and await further study. 4.2 Non-adamantane-based inhibitors Several non-adamantane"/>
 <result pre="which is reported to block viroporins and/or replication of IAV," exact="hepatitis" post="C virus, HIV-1, Dengue virus, and severe acute respiratory"/>
 <result pre="block viroporins and/or replication of IAV, hepatitis C virus, HIV-1," exact="Dengue" post="virus, and severe acute respiratory syndrome coronavirus (SARS-CoV; Gazina"/>
 <result pre="of IAV, hepatitis C virus, HIV-1, Dengue virus, and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV; Gazina and Petrou, 2012; Pervushin"/>
 <result pre="IAV, hepatitis C virus, HIV-1, Dengue virus, and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV; Gazina and Petrou, 2012; Pervushin et"/>
 <result pre="hepatitis C virus, HIV-1, Dengue virus, and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV; Gazina and Petrou, 2012; Pervushin et al.,"/>
 <result pre="18 μM). Additionally compound 26, although inhibiting WT M2 with" exact="lower" post="efficacy (20% inhibition at 100 μM) than 25 in"/>
 <result pre="oseltamivir in vitro. However, while salinomycin on its own exhibited" exact="limited" post="antiviral activity in vivo; it did rescue mice treated"/>
 <result pre="detected for compounds 13, 24, and 25 by TEVC are" exact="lower" post="than their PRA EC50 values. Discrepancies in both cases"/>
 <result pre="measurements are labor intense and are often reserved as a" exact="secondary" post="assay to characterize lead candidates that have already shown"/>
 <result pre="different mutations. For example, compound 9 inhibits M2 Val27Ala with" exact="lower" post="IC50s than M2 WT (0.3 and 18 μM, respectively),"/>
 <result pre="the drug resistant mutants of M2. When designing drugs against" exact="viral" post="targets, an inherent challenge is the higher degree of"/>
 <result pre="challenge is the higher degree of structural flexibility exhibited by" exact="viral" post="proteins in comparison to many prokaryotic and eukaryotic targets"/>
 <result pre="In contrast to thermostable proteins that encompass tight hydrophobic cores," exact="viral" post="proteins are frequently loosely packed, resulting not only in"/>
 <result pre="site, technical difficulties in effective measurement of drug inhibition, and" exact="absence of" post="reliable protocols to assess protein drug interactions. To overcome"/>
 <result pre="for larger complexes to predict and visualize the interaction of" exact="viral" post="protein domains and putative inhibitors, complexes of proteins, and"/>
 <result pre="putative inhibitors, complexes of proteins, and simulation of complexes of" exact="viral" post="proteins and cellular factors. Taken together, several emerging technologies"/>
 <result pre="&quot;gold standards&quot; for these studies and should be applied as" exact="secondary" post="assays to rule out false positives obtained from higher-throughput"/>
 <result pre="current antivirals and with the ability to inhibit existing drug-resistant" exact="viral" post="strains, may be essential toward mitigating the next inevitable"/>
 <result pre="low toxicity (9, 16, 23), and rescue mice from lethal" exact="infection" post="(9). Going forward, further discovery of new chemical scaffolds"/>
 <result pre="Chemical Inhibitors of Heterologous Proteins Expressed in Yeast Using a" exact="Simple" post="Growth-Restoration Assay2009Humana PressTotowa, NJ12513710.1007/978-1-60327-545-3_9 BalgiA.D.WangJ.ChengD.Y.H.MaC.PfeiferT.A.ShimizuY.AndersonH.J.PintoL.H.LambR.A.DeGradoW.F.RobergeM.Inhibitors of the influenza A"/>
 <result pre="of membrane protein crystallographyCurr. Opin. Struct. Biol.18200858158610.1016/j.sbi.2008.07.00118674618 Castaño-RodriguezC.HonrubiaJ.M.Gutiérrez-ÁlvarezJ.DeDiegoM.L.Nieto-TorresJ.L.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Fernandez-DelgadoR.Verdia-BáguenaC.Queralt-MartínM.KochanG.PerlmanS.AguilellaV.M.SolaI.EnjuanesL.Role of severe" exact="acute" post="respiratory syndrome coronavirus viroporins E, 3a, and 8a in"/>
 <result pre="membrane protein crystallographyCurr. Opin. Struct. Biol.18200858158610.1016/j.sbi.2008.07.00118674618 Castaño-RodriguezC.HonrubiaJ.M.Gutiérrez-ÁlvarezJ.DeDiegoM.L.Nieto-TorresJ.L.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Fernandez-DelgadoR.Verdia-BáguenaC.Queralt-MartínM.KochanG.PerlmanS.AguilellaV.M.SolaI.EnjuanesL.Role of severe acute" exact="respiratory" post="syndrome coronavirus viroporins E, 3a, and 8a in replication"/>
 <result pre="protein crystallographyCurr. Opin. Struct. Biol.18200858158610.1016/j.sbi.2008.07.00118674618 Castaño-RodriguezC.HonrubiaJ.M.Gutiérrez-ÁlvarezJ.DeDiegoM.L.Nieto-TorresJ.L.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Fernandez-DelgadoR.Verdia-BáguenaC.Queralt-MartínM.KochanG.PerlmanS.AguilellaV.M.SolaI.EnjuanesL.Role of severe acute respiratory" exact="syndrome" post="coronavirus viroporins E, 3a, and 8a in replication and"/>
 <result pre="Amantadine-Resistance Mutations in the Influenza A M2 Sequence201410.1186/1471-2156-16-S2-S3 FioreA.E.FryA.ShayD.GubarevaL.BreseeJ.S.UyekiT.M.Centers for" exact="Disease" post="Control and Prevention (CDC)Antiviral agents for the treatment and"/>
 <result pre="resistanceAntimicrob. Agents Chemother.5320094457446310.1128/AAC.00650-0919651904 GanS.-W.TanE.LinX.YuD.WangJ.TanG.M.-Y.VararattanavechA.YeoC.Y.SoonC.H.SoongT.W.PervushinK.TorresJ.The small hydrophobic protein of the human" exact="respiratory" post="syncytial virus forms pentameric ion channelsJ. Biol. Chem.2872012246712468910.1074/jbc.M111.33279122621926 GandhiC.S.ShuckK.LearJ.D.DieckmannG.R.DeGradoW.F.LambR.A.PintoL.H.Cu(II)"/>
 <result pre="amilorideMol. Pharmacol.902016809510.1124/mol.115.10273127193582 JangY.Soo ShinJ.YoonY.-S.Young GoY.Won LeeH.Seung KwonO.ParkS.ParkM.-S.KimM.Jae JungE.U.Salinomycin inhibits influenza" exact="virus infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="Pharmacol.902016809510.1124/mol.115.10273127193582 JangY.Soo ShinJ.YoonY.-S.Young GoY.Won LeeH.Seung KwonO.ParkS.ParkM.-S.KimM.Jae JungE.U.Salinomycin inhibits influenza virus" exact="infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="JungE.U.Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and" exact="viral" post="matrix protein 2 function salinomycin inhibits influenza virus infection"/>
 <result pre="acidification and viral matrix protein 2 function salinomycin inhibits influenza" exact="virus infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="and viral matrix protein 2 function salinomycin inhibits influenza virus" exact="infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="salinomycin inhibits influenza virus infection by disrupting endosomal acidification and" exact="viral" post="matrix protein 2 function VACCINES ANDjvi.asm.org 1 J. Virol.9220181441145910.1128/JVI.01441-18"/>
 <result pre="ion channelProc. Natl. Acad. Sci. Unit. States Am.1052008109671097210.1073/pnas.0804958105 JoubertD.A.BlasdellK.R.AudsleyM.D.TrinidadL.MonaghanP.DaveK.A.LieuK.G.Amos-RitchieR.JansD.A.MoseleyG.W.GormanJ.J.WalkerP.J.Bovine Ephemeral" exact="Fever" post="Rhabdovirus 1 Protein Has Viroporin-like Properties and Binds Importin"/>
 <result pre="Acad. Sci. Unit. States Am.1052008109671097210.1073/pnas.0804958105 JoubertD.A.BlasdellK.R.AudsleyM.D.TrinidadL.MonaghanP.DaveK.A.LieuK.G.Amos-RitchieR.JansD.A.MoseleyG.W.GormanJ.J.WalkerP.J.Bovine Ephemeral Fever Rhabdovirus 1" exact="Protein" post="Has Viroporin-like Properties and Binds Importin 1 and Importin"/>
 <result pre="and Binds Importin 1 and Importin 7201410.1128/JVI.01812-13 KabschK.AlonsoA.The human papillomavirus" exact="type 16" post="E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT"/>
 <result pre="ion channel activity in Xenopus laevis oocytesPLoS One132018e019922710.1371/journal.pone.0199227 KeyserL.A.KarlM.NafzigerA.N.BertinoJ.S.Comparison of" exact="central nervous system" post="Adverse effects of amantadine and rimantadine used as sequential"/>
 <result pre="M2-S31N channel blockersMol. Pharmacol.90201618819810.1124/mol.116.10534627385729 MadanV.BartenschlagerR.CarrascoL.NievaJ.L.Structural and functional properties of the" exact="hepatitis" post="C virus p7 viroporinViruses720154461448110.3390/v708282626258788 MartinK.HeleniustA.Nuclear transport of influenza virus"/>
 <result pre="virus p7 viroporinViruses720154461448110.3390/v708282626258788 MartinK.HeleniustA.Nuclear transport of influenza virus ribonucleoproteins: the" exact="viral" post="matrix protein (ml) promotes export and inhibits importCell1991 MouldJ.a.PatersonR.G.TakedaM.OhigashiY.VenkataramanP.LambR.a.PintoL.H.Influenza"/>
 <result pre="A/H3N2 influenza virusesVirology388200927027810.1016/j.virol.2009.03.02619394063 Nieto-TorresJ.Verdiá-BáguenaC.Castaño-RodriguezC.AguilellaV.EnjuanesL.Relevance of viroporin ion channel activity on" exact="viral" post="replication and pathogenesisViruses720153552357310.3390/v707278626151305 NievaJ.L.MadanV.CarrascoL.Viroporins: Structure and biological functionsNat. Rev."/>
 <result pre="virusesJ. Biol. Chem.28120068997900010.1074/jbc.R50002020016407184 PremkumarA.WilsonL.EwartG.GageP.Cation-selective ion channels formed by p7 of" exact="hepatitis" post="C virus are blocked by hexamethylene amilorideFEBS Lett.55720049910310.1016/S0014-5793(03)01453-414741348 PriestB.T.CerneR.KrambisM.J.SchmalhoferW.A.WakulchikM.WilenkinB.BurrisK.D.Automated"/>
 <result pre="haemagglutinin by amantadineEMBO J.91990346934762209554 SulliC.BanikS.S.R.SchillingJ.MoserA.XiangX.PayneR.WanlessA.WillisS.H.PaesC.RuckerJ.B.DoranzB.J.Detection of proton movement directly across" exact="viral" post="membranes to identify novel influenza virus M2 inhibitorsJ. Virol.872013106791068610.1128/JVI.01190-1323885079"/>
 <result pre="TakedaM.LeserG.P.RussellC.J.LambR.A.Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient" exact="viral" post="fusionProc. Natl. Acad. Sci. U.S.A.1002003146101461710.1073/pnas.223562010014561897 TangY.ZaitsevaF.LambR.A.PintoL.H.The gate of the"/>
 <result pre="Bioorg. Med. Chem. Lett.17200769269610.1016/j.bmcl.2006.10.09217113287 ThielG.BaumeisterD.SchroederI.KastS.M.Van EttenJ.L.MoroniA.Minimal art: or why small" exact="viral" post="K+ channels are good tools for understanding basic structure"/>
 <result pre="novel HIV-1 inhibitorsPLoS One102015e012109910.1371/journal.pone.0121099 ToJ.TorresJ.Viroporins in the influenza virusCells8201965410.3390/cells8070654 TokurikiN.OldfieldC.J.UverskyV.N.BerezovskyI.N.TawfikD.S.Do" exact="viral" post="proteins possess unique biophysical features?Trends Biochem. Sci.342009535910.1016/j.tibs.2008.10.00919062293 TuQ.PintoL.H.LuoG.ShaughnessyM.A.MullaneyD.KurtzS.KrystalM.LambR.A.Characterization of"/>
 <result pre="amantadine HCl and rimantadine HCl in naturally occurring influenza A2" exact="respiratory" post="illness in manN. Engl. J. Med.281196957958410.1056/NEJM1969091128111024897137 WrightA.K.BatsomboonP.DaiJ.HungI.ZhouH.-X.DudleyG.B.CrossT.A.Differential binding of"/>
 <result pre="cells Madin-Darby canine kidney cells NMR nuclear magnetic resonance PDB" exact="Protein" post="Data Bank PRA plaque reduction assay SARS-CoV severe acute"/>
 <result pre="PDB Protein Data Bank PRA plaque reduction assay SARS-CoV severe" exact="acute" post="respiratory syndrome coronavirus SEVC single electrode voltage clamp TEVC"/>
 <result pre="Protein Data Bank PRA plaque reduction assay SARS-CoV severe acute" exact="respiratory" post="syndrome coronavirus SEVC single electrode voltage clamp TEVC two"/>
 <result pre="Data Bank PRA plaque reduction assay SARS-CoV severe acute respiratory" exact="syndrome" post="coronavirus SEVC single electrode voltage clamp TEVC two electrode"/>
</results>
